← 返回

一种双靶向仿生纳米平台整合 SDT/CDT/气体治疗以增强协同铁死亡用于原位肝细胞癌治疗

英文原题:A Dual-Targeting Biomimetic Nanoplatform Integrates SDT/CDT/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy.

查看英文原题

A Dual-Targeting Biomimetic Nanoplatform Integrates SDT/CDT/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy.

PubMed 2025/01/09(内容时间) Adv Sci (Weinh) Q1 · IF 14.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

开发促进铁死亡细胞死亡的高效治疗策略为肝细胞癌(HCC)治疗提供了巨大潜力。在此,本研究提出了一种HCC靶向纳米平台,该平台将双金属FeMoO 4纳米颗粒与CO释放分子整合,并进一步用SP94肽修饰的巨噬细胞膜进行伪装,以增强铁死亡驱动的HCC多模态治疗。利用多价金属元素的多酶活性,该纳米平台不仅能分解H 2 O 2产生氧气并缓解肿瘤缺氧,还能消耗谷胱甘肽以使谷胱甘肽过氧化物酶4失活,从而在超声(US)照射下放大声动力治疗和铁死亡肿瘤死亡。

同时,该纳米平台催化Fenton反应产生羟基自由基用于化学动力治疗。细胞内活性氧升高触发CO的级联释放,导致致死性脂质过氧化并进一步增强铁死亡介导的肿瘤治疗。该纳米平台在US照射下在皮下和原位HCC模型中均表现出强大的抗肿瘤疗效和良好的生物安全性,代表了一种有前景的HCC治疗方法。

此外,这些发现为肿瘤微环境调控以优化US触发的多模态癌症治疗提供了新见解。

展开英文摘要原文

The development of efficient therapeutic strategies to promote ferroptotic cell death offers significant potential for hepatocellular carcinoma (HCC) treatment.

Herein, this study presents an HCC-targeted nanoplatform that integrates bimetallic FeMoO 4 nanoparticles with CO-releasing molecules, and further camouflaged with SP94 peptide-modified macrophage membrane for enhanced ferroptosis-driven multi-modal therapy of HCC. Leveraging the multi-enzyme activities of the multivalent metallic elements, the nanoplatform not only decomposes H 2 O 2 to generate oxygen and alleviate tumor hypoxia but also depletes glutathione to inactivate glutathione peroxides 4, which amplify sonodynamic therapy and ferroptotic tumor death under ultrasound (US) irradiation.

Meanwhile, the nanoplatform catalyzes the Fenton reaction to produce hydroxyl radicals for chemodynamic therapy. Elevated intracellular reactive oxygen species trigger the cascade release of CO, leading to lethal lipid peroxidation and further enhancing ferroptosis-mediated tumor therapy. This nanoplatform demonstrates robust anti-tumor efficacy under US irradiation with favorable biosafety in both subcutaneous and orthotopic HCC models, representing a promising therapeutic approach for HCC.

Additionally, the findings offer new insights into tumor microenvironment modulation to optimize US-triggered multi-modal cancer therapy.

论文信息

作者
Meng W、Chen T、Li X、Li Y、Zhang L、Xu Y、Song T、Qi J
单位
Tianjin Key Laboratory of Biomedical Materials and Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.China
期刊
Advanced science (Weinheim, Baden-Wurttemberg, Germany)2025 Feb
原文标识
PubMed 39783849 · DOI 10.1002/advs.202413833